Search | Clinical Trials Finder

Conditions: Hypereosinophilic Syndrome
Interventions: Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more

Conditions: Pyoderma Gangrenosum
Interventions: Spesolimab, Placebo matching to spesolimab, Prednisone, Prednisolone; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 23 more

Conditions: Kidney Transplant
Interventions: Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more

Conditions: Macrophage Activation Syndrome
Interventions: kineret, placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Year and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Systemic Lupus Erythematosus Arthritis
Interventions: Methylprednisolone, Placebos; Drug
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Prostate Cancer
Interventions: Abiraterone, Apitolisib, Ipatasertib, Placebo, Prednisone, Prednisolone; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 12
States / cities: Scottsdale, Arizona • San Francisco, California • Fort Myers, Florida + 9 more

Conditions: Hoffa's Fat Pad Impingement
Interventions: methylprednisolone acetate and lidocaine, Saline injection (Octreotide LAR placebo); Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Norwood, Massachusetts

Conditions: Prostatic Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Matching placebo (normal saline), Abiraterone, Prednisone/Prednisolone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 806 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 29
States / cities: Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more

Conditions: Asthma, Wheezing
Interventions: Azithromycin, Prednisolone, Placebo Azithromycin, Placebo Prednisolone; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 12 Months to 71 Months
Enrollment: 607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 16
States / cities: Tucson, Arizona • Oakland, California • San Francisco, California + 11 more

Conditions: Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions: High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 1 Year to 18 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 14 more

Conditions: Fever, Labor Pain, Complication of Anesthesia During Pregnancy, Unspecified
Interventions: Methylprednisolone, Normal saline; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis
Interventions: Steroid arm, Placebo; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 8 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alcoholic Hepatitis
Interventions: Anakinra and Zinc, Prednisone, Placebos; Drug
Lead sponsor: Indiana University; Other
Eligibility: 21 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Phoenix, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 7 more

Conditions: Wound Healing
Interventions: Arnica Montana, Bromelain, Placebo; Dietary Supplement · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lupus Nephritis
Interventions: Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine, Placebo to Azathioprine, Placebo to Mycophenolate mofetil, Corticosteroid; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 28
States / cities: Huntsville, Alabama • La Jolla, California • Los Angeles, California + 22 more

Conditions: Asthma
Interventions: Prednisolone high dose, Prednisolone lower dose; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 18 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lupus Nephritis
Interventions: Laquinimod, Mycophenolate Mofetil, Prednisolone/Prednisone, Placebo, Methylprednisolone; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 10 more

Conditions: Infantile Spasms, Infantile Epileptic Spasms Syndrome, West Syndrome
Interventions: Prednisolone, Famotidine, Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 2 Months to 18 Months
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain
Interventions: Placebo, Medrol; Drug
Lead sponsor: University of Utah; Other
Eligibility: 10 Years to 21 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Polyp of Nasal Sinus
Interventions: Doxycycline, methylprednisolone, nasal saline spray, Flonase, sugar pill; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Immunoscience
Interventions: Prenisolone, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Austin, Texas

Conditions: Atrial Fibrillation
Interventions: Solumedrol, Placebo; Drug
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Biliary Atresia
Interventions: Corticosteroids, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Up to 6 Months
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Glycogen Storage Disease Type IA
Interventions: DTX401, Placebo, Oral prednisolone, Placebo for oral prednisolone; Genetic · Other · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 8 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 9
States / cities: Orange, California • Aurora, Colorado • Farmington, Connecticut + 6 more

Search by objective public record fields.

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

Treatment of Macrophage Activation Syndrome (MAS) With Anakinra

MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Hoffa's Fat Pad Impingement (HFPI)

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.

TReatment for ImmUne Mediated PathopHysiology

Maternal Epidural Steroids and Hyperthemia

Steroid Treatment for Sickle Cell Pain Crisis

Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis

Arnica Montana and Bromelain in Rhinoplasty

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

Oral Prednisolone Dosing in Children Hospitalized With Asthma

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis

A Study to Prevent Infantile Spasms Relapse

Medrol Dose Packs for Post-Operative Pain Control

Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps

A Study to Assess the Pharmacodynamics (PD) of Prednisoline in Healthy Male Subject

Corticosteroid Pulse After Ablation

A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy

A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)